TOKYO, May 15 (Pulse News Wire) – Prism Biolab Co.,ltd (206A.T) announced today that its research and license agreement with Boehringer Ingelheim International GmbH (BI) has ended upon the expiration of the contract term on May 15, 2026. The agreement, signed on May 18, 2020, aimed to screen potential drug targets using PRISM BioLab's low-molecule library compounds.
Under the contract, PRISM BioLab provided compounds to BI in exchange for compensation related to their use. Despite discussions regarding the continuation of the agreement, BI decided against renewal, leading to the termination of the contract on May 16, 2026.
No additional monetary transactions will occur due to the contract’s end, and PRISM BioLab does not anticipate any impact on its current operating performance. --- PRISM BioLab stated that the termination was based on BI's decision and did not affect ongoing operations or future plans.
The company will continue to focus on its existing projects and strategic initiatives.
🟡 Confidence: Standard AI-translated content.